PATENT CLAIM ANALYSIS

Application Number: 15861444
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["544", "283000"]

Abstract:
Polymorphs of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine are provided herein. Processes for preparing the polymorphs and pharmaceutical composition comprising the polymorphs are also disclosed.

Claim (Index 1):
A method of treating a disease or disorder modulated by ErbB2, comprising administering to a mammal in need of such treatment an effective amount of a crystalline polymorph of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine freebase, wherein the disease or disorder modulated by ErbB2 is breast cancer, and wherein the polymorph is Form C.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 86.0
- Lexical Diversity: 1.32258
- Patent Class: 544.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14923172', '14351835', '14351840', '12933044', '14570019']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7538417109153144
- 35 USC 102 Novelty (BERT): 0.6500013378905378
- Combined Prediction Score: 0.7434576736128368
- Mean Citation Score: 418.13936
- Max Citation Score: 620.1506
- Similarity Product: 598.8787509139419

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test